Interestingly, TG2 has been shown to increase CD44 activity in breast cancer cells, regulating the promotion of stem cell phenotype and metastatic potential [90], and inhibition of TG2 lead to depleted CSC surface antigens such as CD44 in renal cell carcinoma [45]. The gene discussed is TGM2; the disease is breast cancer.